Vaxart, Inc. Files 8-K: Material Definitive Agreement
Ticker: VXRT · Form: 8-K · Filed: Sep 30, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $456.1 m, $3.2 m, $96.5 m, $30.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing, biotech
Related Tickers: VXRT
TL;DR
Vaxart signed a big deal, filing an 8-K today.
AI Summary
On September 27, 2024, Vaxart, Inc. entered into a Material Definitive Agreement. The filing also includes information on other events and financial statements and exhibits. Vaxart, Inc. is a biotechnology company focused on developing oral vaccines.
Why It Matters
This 8-K filing indicates a significant new agreement for Vaxart, Inc., which could impact its development pipeline and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and opportunities, requiring further analysis of the agreement's terms.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- September 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-35285 (company_id) — SEC File Number
- 59-1212264 (company_id) — IRS Employer Identification No.
- 170 Harbor Way, Suite 300, South San Francisco, CA (address) — Business and Mail Address
FAQ
What is the nature of the Material Definitive Agreement entered into by Vaxart, Inc. on September 27, 2024?
The filing indicates the entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the provided text snippet.
What was Vaxart, Inc.'s former company name before its name change on April 13, 2016?
Vaxart, Inc.'s former company name was Aviragen Therapeutics, Inc.
When was Vaxart, Inc. incorporated?
Vaxart, Inc. was incorporated in Delaware.
What is Vaxart, Inc.'s fiscal year end?
Vaxart, Inc.'s fiscal year ends on December 31.
What is the SIC code for Vaxart, Inc.?
The Standard Industrial Classification (SIC) code for Vaxart, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 941 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-09-30 17:20:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
- $456.1 m — funding to the Company to approximately $456.1 million, representing an increase of appr
- $3.2 m — presenting an increase of approximately $3.2 million, and (ii) increased the total amo
- $96.5 m — available for payment to approximately $96.5 million, representing an increase of appr
- $30.8 million — presenting an increase of approximately $30.8 million. A portion of the additional funding is
Filing Documents
- vxrt20240930_8k.htm (8-K) — 30KB
- ex_728568.htm (EX-99.1) — 14KB
- 0001437749-24-030276.txt ( ) — 184KB
- vxrt-20240927.xsd (EX-101.SCH) — 3KB
- vxrt-20240927_def.xml (EX-101.DEF) — 12KB
- vxrt-20240927_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240927_pre.xml (EX-101.PRE) — 12KB
- vxrt20240930_8k_htm.xml (XML) — 3KB
01
Item 1.01. Entry into a Material Definitive Agreement. On September 27, 2024, Vaxart, Inc. (the "Company") entered into Modification No. 3 (the "Modification") to the ATI-RRPV Project Award Agreement No. 001 dated June 13, 2024 (the "Project Agreement") with Advanced Technology International, the Rapid Response Partnership Vehicle's Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority ("BARDA") of the U.S. Department of Health and Human Services. As previously disclosed, pursuant to the Project Agreement, the Company will receive funding to conduct a Phase 2b comparative study (the "Trial") evaluating the Company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration. The Modification (i) increased the total estimated ceiling for the funding to the Company to approximately $456.1 million, representing an increase of approximately $3.2 million, and (ii) increased the total amount of funding currently allotted to the Trial and available for payment to approximately $96.5 million, representing an increase of approximately $30.8 million. A portion of the additional funding is for the Company to commence manufacturing of a vaccine construct targeting the KP.2 strain. On September 27, 2024, BARDA also informed the Company that it could proceed with the sentinel portion of the Trial pursuant to the Project Agreement. Pursuant to the Modification, the Trial is to begin with a sentinel cohort of 400 individuals using the Company's XBB vaccine and an mRNA XBB comparator. The foregoing description of the Modification does not purport to be complete and is qualified in its entirety by reference to the full text of the Modification, which will be filed as an exhibit to the Company's next periodic report.
01
Item 8.01. Other Events. On September 30, 2024, the Company issued a press release announcing the initiation of the sentinel portion of the Trial. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and, other than the quotes by Dr. James F. Cummings, is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated September 30, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: September 30, 2024 By: /s/ Steven Lo Steven Lo President and Chief Executive Officer